Literature DB >> 7901897

Subjective response to neuroleptics in schizophrenia.

A G Awad1.   

Abstract

Subjective response to neuroleptics in patients with schizophrenia is reviewed in terms of its validity and measurement. Evidence is presented to support a correlation between altered subjective state on neuroleptics, and therapeutic outcome and medication compliance. Factors that have been implicated in the genesis of such altered subjective states include demographics, psychiatric characteristics, type and dose of neuroleptic, extrapyramidal symptoms (particularly akathisia), depressive states, and patients' values and attitudes toward health and illness. Factors that may contribute to lack of interest in researching subjective experiences of schizophrenia patients on medications are reviewed, and methodological improvements in study design are proposed to enhance our understanding of this phenomenon. Such understanding may help us to better appreciate the many factors that contribute to variability of responses to neuroleptic therapy in patients with schizophrenia and also help us to develop more effective treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901897     DOI: 10.1093/schbul/19.3.609

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  69 in total

Review 1.  Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.

Authors:  A George Awad
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

2.  [The initial dysphoric reaction (IDR) to the first dose of neuroleptics].

Authors:  B Graf Schimmelmann; M Schacht; C Perro; M Lambert
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 3.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

4.  Social interaction and drug attitude effectiveness in patients with schizophrenia.

Authors:  Jui-Kang Tsai; Wen-Kuo Lin; For-Wey Lung
Journal:  Psychiatr Q       Date:  2011-12

5.  Illness experience and reasons for nonadherence among individuals with bipolar disorder who are poorly adherent with medication.

Authors:  Martha Sajatovic; Jennifer Levin; Edna Fuentes-Casiano; Kristin A Cassidy; Curtis Tatsuoka; Janis H Jenkins
Journal:  Compr Psychiatry       Date:  2010-09-01       Impact factor: 3.735

6.  Rationale and parameters for medication-free research in psychosis.

Authors:  Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2006-02-03       Impact factor: 9.306

Review 7.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04       Impact factor: 5.270

8.  Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Authors:  Martha Sajatovic; Jennifer Levin; Luis F Ramirez; David Y Hahn; Curtis Tatsuoka; Christopher S Bialko; Kristin A Cassidy; Edna Fuentes-Casiano; Tiffany D Williams
Journal:  J Clin Psychiatry       Date:  2013-12       Impact factor: 4.384

9.  Facilitated psychiatric advance directives: a randomized trial of an intervention to foster advance treatment planning among persons with severe mental illness.

Authors:  Jeffrey W Swanson; Marvin S Swartz; Eric B Elbogen; Richard A Van Dorn; Joelle Ferron; H Ryan Wagner; Barbara J McCauley; Mimi Kim
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

10.  Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models.

Authors:  Alessandro Rossi; Roberta Pacifico; Paolo Stratta
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.